TG Therapeutics: Pay

TG Therapeutics paid its 2 named executives $29.3M in total in FY2025 (Dec). CEO Michael S. Weiss was paid $25.6M of that.

Pay$100 in the stock at the end of FY20 → $57
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Michael S. WeissChief Executive Officer and President
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Sean A. PowerChief Financial Officer, Treasurer and Corporate Secretary
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 9 peers with pay on file was $13.4M. The CEO of TG Therapeutics was paid $25.6M, 92% above the median.

  1. 1TG Therapeutics
  2. 2Halozyme Therapeutics
  3. 3Madrigal Pharmaceuticals
  4. 4BridgeBio Pharma
  5. 5INSMED
  6. 6Ionis Pharmaceuticals
  7. 7Ultragenyx Pharmaceutical
  8. 8Krystal Biotech
  9. 9Adma Biologics
  10. 10Neurocrine Biosciences
  11. 11Acadia PharmaceuticalsNot disclosed
  12. 12Amicus Therapeutics, Inc.Not disclosed
  13. 13Apellis Pharmaceuticals, Inc.Not disclosed
  14. 14Axsome TherapeuticsNot disclosed
  15. 15Blueprint Medicines CorporationNot disclosed
  16. 16Corcept TherapeuticsNot disclosed
  17. 17SpringWorks TherapeuticsNot disclosed
  18. 18VericelNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.